循环肿瘤细胞与临床输血风险

Risk of Circulating Tumor Cells and Clinical Blood Transfusion

  • 摘要: 循环肿瘤细胞( circulating tumor cells,CTCs)具有播种肿瘤的能力,其可存在于癌前病变患者和健康人群外周血中,但目前对于献血者的血液检查项目尚未开展CTCs相关筛查。在世界范围内,每年发生大量的同种异体输血,使受者暴露于献血者CTCs传播和感染相关肿瘤的风险之中。白细胞滤除虽不能完全去除血液中的CTCs,但可有效减少血液中白细胞数量并降低其增值能力;血液辐照可高效破坏血液中CTCs的DNA,防止因输注含有CTCs的异体血液而导致肿瘤发生和转移。因此,应重视CTCs对于临床输血的潜在风险,加强血液临床前处理,避免因输血而导致受者感染供者相关肿瘤事件的发生。

     

    Abstract: Circulating tumor cells (CTCs) have the ability to sow tumors and can be found in the peripheral blood of patients with precancerous lesions and healthy people. However, CTCs are not currently screened in the donors blood. A large number of allogeneic blood transfusions occurred worldwide each year, and allogeneic blood transfusions expose recipients to the risk of transmission and affect tumors associated with donor CTCs. Although leukocyte filtration can not completely remove tumor cells in the blood, it can effectively reduce the number of white blood cells in the blood and reduce their proliferation ability. Blood irradiation can effectively destroy the DNA of CTCs in the blood, and inhibit the occurrence and metastasis of tumors caused by the infusion of allogeneic blood containing CTCs. Therefore, we should pay attention to the potential risk of CTCs on clinical transfusion, and strengthen the preclinical treatment of blood to avoid donor-related tumor infection in blood recipients due to clinical transfusion.

     

/

返回文章
返回